Abstract
Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimers disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model.
Keywords: Cytokine, diabetes, endotoxin, inflammation, LPS, interleukin-6, sepsis, tumor necrosis factor-α
Current Medicinal Chemistry
Title: Human Endotoxemia as a Model of Systemic Inflammation
Volume: 15 Issue: 17
Author(s): A. S. Andreasen, K. S. Krabbe, R. Krogh-Madsen, S. Taudorf, B. K. Pedersen and K. Moller
Affiliation:
Keywords: Cytokine, diabetes, endotoxin, inflammation, LPS, interleukin-6, sepsis, tumor necrosis factor-α
Abstract: Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimers disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model.
Export Options
About this article
Cite this article as:
Andreasen S. A., Krabbe S. K., Krogh-Madsen R., Taudorf S., Pedersen K. B. and Moller K., Human Endotoxemia as a Model of Systemic Inflammation, Current Medicinal Chemistry 2008; 15 (17) . https://dx.doi.org/10.2174/092986708784872393
DOI https://dx.doi.org/10.2174/092986708784872393 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neopterin as a Marker for Immune System Activation
Current Drug Metabolism The Role of EC-IC Bypass in Critical Cerebral Hemodynamics of Different Origin
Current Hypertension Reviews A Comparative Assessment of Metabolic Syndrome and its Association with Vitamin D and Other Risk Factors in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Death Due to COVID-19 in an Infant with Combined Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Current Drug Targets Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Individual Differences in the Neurobiology of Social Stress: Implications for Depression-Cardiovascular Disease Comorbidity
Current Neuropharmacology Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Current Medicinal Chemistry Recent Patents on Blueberry Picking
Recent Patents on Mechanical Engineering Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Trends in the Design, Synthesis and Biological Exploration of β-Lactams
Current Medicinal Chemistry Biochemical Markers of Renal Function
Current Medicinal Chemistry Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design